Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Image Bank

All categories
  • Board of Directors
  • Logo
  • Management
  • Other
Jeppe Øvlesen View
Jeppe Øvlesen CEO
Download hi res
Download low res
Jeppe Øvlesen View
Jeppe Øvlesen CEO
Download hi res
Download low res
View
Jeppe Øvlesen CEO
Download hi res
Download low res
Thomas Boesen View
Thomas Boesen COO
Download hi res
Download low res
View
Thomas Boesen COO
Download hi res
Download low res
View
Thomas Boesen COO
Download hi res
Download low res
Thomas Jonassen View
Thomas Jonassen CSO
Download hi res
Download low res
View
Thomas Jonassen CSO
Download hi res
Download low res
View
Thomas Jonassen CSO
Download hi res
Download low res
Patrik Renblad View
Patrik Renblad CFO
Download hi res
Download low res
View
Patrik Renblad CFO
Download hi res
Download low res
View
Patrik Renblad CFO
Download hi res
Download low res
Jim Knight View
Jim Knight CBO
Download hi res
Download low res
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe